Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer
Status:
Completed
Trial end date:
2020-09-15
Target enrollment:
Participant gender:
Summary
The study is intended as a Proof of Concept and dose confirmation study. The primary
objective of this study is to observe safety and tolerability of idronoxil (NOX66) in
combination with radiotherapy (at palliative doses) in patients with metastatic
castrate-resistant prostate cancer (CRPC) and to confirm dose in order to progress to Phase
2/3.